Scarica l'app Stockscreener
18.12
0.93%
-0.17
Dopo l'orario di chiusura:
19.02
0.90
+4.97%
Bioage Labs Inc Borsa (BIOA) Ultime notizie
BioAge Labs Reports Strong Q3 2024 Achievements - Yahoo Finance
BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates - The Manila Times
BioAge Labs Reports Q3 Loss, Secures $334.5M Cash Runway Through 2029 After IPO | BIOA Stock News - StockTitan
BioArctic AB Sets Q3 2024 Earnings Call for November 14: Key Details Inside | BIOA Stock News - StockTitan
BioAge Labs, Inc. to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024 - Marketscreener.com
BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024 - GlobeNewswire
BioAge Labs to Present at Jefferies London Healthcare Conference - GlobeNewswire
Citi sets BioAge Labs Buy stock rating on obesity drug potential - Investing.com
BioAge Labs initiated with an Overweight at Morgan Stanley - MSN
Goldman Sachs, Morgan Stanley bullish on BioAge, cite Lilly relationship - MSN
Goldman Sachs, Morgan Stanley bullish on BioAge, cite Lilly relationship (NASDAQ:BIOA) - Seeking Alpha
Morgan Stanley sets BioAge stock at Overweight rating, cites Lilly tie-up - Investing.com Australia
Wall Street analysts initiate coverage of BioAge Labs By Investing.com - Investing.com Canada
BioAge Labs stock initiated at buy, key obesity trial data expected by 2025 – Jefferies - Investing.com Canada
Morgan Stanley sets BioAge stock at Overweight rating, cites Lilly tie-up By Investing.com - Investing.com South Africa
Prediction: These 2 Stocks Could Soar in 2025 - Yahoo Finance
Stocks To Watch: BioAge Labs Sees Relative Strength Rating Jump To 94 - Investor's Business Daily
Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock - Yahoo! Voices
RA Capital Management, L.P. Acquires New Stake in Bioage Labs Inc - Yahoo Finance
BioAge Labs’ $238 Million Upsized Initial Public Offering - Global Legal Chronicle
3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October - MSN
Bioage Labs director acquires $4.3m in common stock By Investing.com - Investing.com UK
Bioage Labs director acquires $4.3m in common stock - Investing.com
This IPO Biotech Stock Could Be the Next Eli Lilly - The Motley Fool
Cormorant Asset Management buys $8.1m in BioAge Labs stock - Investing.com India
BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of the Concurrent Private Placement - The Manila Times
BioAge Labs Announces Closing of Initial Public Offering, - GlobeNewswire
BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of the Concurrent Private Placement - ForexTV.com
Cormorant Asset Management buys $8.1m in BioAge Labs stock By Investing.com - Investing.com South Africa
Fenwick Represents BioAge Labs in $238 Million Upsized Initial Public Offering and Concurrent Private Placement - Fenwick & West LLP
BioAge Labs: Weighing The Risks And Rewards Of A Biotech Revival (NASDAQ:BIOA) - Seeking Alpha
BioAge Labs director Enright buys $7.2 million in stock - Investing.com India
Finance Watch: BioAge Raises $198m In 20th Biopharma IPO Of 2024 - Scrip
Wave financing, BioAge IPO help biotech end September strong - BioCentury
BioAge Labs director Pande Vijay Satyanand buys $16.2m in stock - Investing.com Australia
BioAge Labs director Pande Vijay Satyanand buys $16.2m in stock By Investing.com - Investing.com South Africa
BioAge Labs director Enright buys $7.2 million in stock By Investing.com - Investing.com Australia
0.79%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):